Skip to main content
Isomer
  1. Home
  2. Automated
  3. NDF A-Z listing
  4. Pantoprazole
P

Pantoprazole

Subsidy Information and Financing Scheme

SDL

Drug Guidance

Yes

Post-marketing information

No

Summary of Biologics

No

Active ingredient: Pantoprazole

General information

Subsidy Information and Financing Scheme

[SDL] Pantoprazole Injection 40 mg

Legend

This section shows the following:

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

Legend list

Indicator

Legend

SDL

Standard Drug List

MAF

Medical Assistance Fund

SVL

Subsidised Vaccine List

MSHL

Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

Drug Guidance for Subsidy

01/04/2020 Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Omeprazole 40 mg injection; and

  • Pantoprazole 40 mg injection

in line with their registered indications in Singapore for gastric anti-secretory treatment when oral therapies are unsuitable.

Subsidy status

[R] Omeprazole 40 mg injection and pantoprazole 40 mg injection are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

[NR] SDL subsidy does not apply to esomeprazole 40 mg injection.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Legend list

Indicator

Legend

R

Recommended for subsidy

NR

Not recommended for subsidy

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Drug availability

Formulation

Public Healthcare Institution

Injection 40 mg

  1. Changi General Hospital

  2. National University Hospital

Enteric Coated Tablet 20 mg

  1. Alexandra Hospital

  2. National University Hospital

Enteric Coated Tablet 40 mg

  1. National Heart Centre

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated

monthly, please refer to HSA Infosearch for the most updated product information.

Oral

* The following products do not have any clinical information available

Intravenous

* The following products do not have any clinical information available

Back to top